

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

28 May 2026

### Effect of levetiracetam versus placebo on the clinical signs of in bipolar patients in the manic episode: a double-blind randomized clinical trial

#### Protocol summary

##### Study aim

To assess the effect of levetiracetam versus placebo on the clinical signs of in bipolar patients in the manic episode

##### Design

This is a double-blind randomized clinical trial, phase II, in which 72 eligible patients will be randomly assigned to the intervention and control groups

##### Settings and conduct

The bipolar patients in manic episode who will refer to Sina Hospital in Hamadan City during the study period will be enrolled in the trial and will be randomly assigned to the intervention and control groups through the block randomization. This trial will be double-blinded so that neither patients nor the physician who will examine the patients will be aware of the intervention.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Age of 16 to 65 years, Bipolar disorder in the manic phase, Young score  $\geq 20$  Exclusion criteria: Bipolar disorder in the depressive phase

##### Intervention groups

Intervention group: Standard treatment plus tablet levetiracetam 250 mg three times daily for 28 days  
Control group: Standard treatment plus tablet placebo three times daily for 28 days

##### Main outcome variables

Primary outcome: Clinical signs) Sleep quality Cognitive function  
Secondary outcome: Gastric complications

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20120215009014N293**  
Registration date: **2019-09-13, 1398/06/22**  
Registration timing: **prospective**

Last update: **2019-09-13, 1398/06/22**

Update count: **0**

##### Registration date

2019-09-13, 1398/06/22

##### Registrant information

###### Name

Jalal Poorolajal

###### Name of organization / entity

Department of Epidemiology & Biostatistics Hamadan University of Medical Sciences

###### Country

Iran (Islamic Republic of)

###### Phone

+98 81 1838 0090

###### Email address

poorolajal@umsha.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2019-10-02, 1398/07/10

##### Expected recruitment end date

2020-10-01, 1399/07/10

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Effect of levetiracetam versus placebo on the clinical signs of in bipolar patients in the manic episode: a double-blind randomized clinical trial

##### Public title

Effect of levetiracetam versus placebo on the clinical signs of in bipolar patients in the manic episode

##### Purpose

Treatment

### **Inclusion/Exclusion criteria**

#### **Inclusion criteria:**

Age of 16 to 65 years, Bipolar disorder in the manic phase, Young score  $\geq 20$

#### **Exclusion criteria:**

Bipolar disorder in the depressive phase

### **Age**

From **16 years** old to **65 years** old

### **Gender**

Both

### **Phase**

2

### **Groups that have been masked**

- Participant
- Care provider
- Investigator
- Outcome assessor

### **Sample size**

Target sample size: **72**

### **Randomization (investigator's opinion)**

Randomized

### **Randomization description**

The patients will be randomly assigned to intervention and control groups using block randomization. For this purpose, we will prepare four sheets of paper, writing on two sheets the name of the intervention and on the other two sheets the name of the control. The paper sheets will be pooled, placed in a container, and randomly drawn one at a time for each patient without replacement until all four sheets are drawn. The four paper sheets will be then placed back into the container, and this action repeated until the sample size is reached.

### **Blinding (investigator's opinion)**

Double blinded

### **Blinding description**

The shape of the medications and placebos will be perfectly the same. Therefore, patients will be unaware of the type of intervention. The physician who will examine the patients will not be aware of the intervention. The analyzer will be unaware of the type of interventions Thus, the trial will be run as triple blind

### **Placebo**

Used

### **Assignment**

Parallel

### **Other design features**

## **Secondary Ids**

empty

## **Ethics committees**

### 1

#### **Ethics committee**

##### **Name of ethics committee**

Ethics Committee of Hamadan University of Medical Sciences

### **Street address**

Vice-chancellor for Research and Technology,  
Hamadan University of Medical Sciences, Shahid  
Fahmideh Ave

### **City**

Hamadan

### **Province**

Hamadan

### **Postal code**

6517838695

### **Approval date**

2019-07-20, 1398/04/29

### **Ethics committee reference number**

IR.UMSHA.REC.1398.336

## **Health conditions studied**

### 1

#### **Description of health condition studied**

Bipolar patients in the manic episode

#### **ICD-10 code**

F31.2

#### **ICD-10 code description**

Bipolar disorder, current episode manic severe with psychotic features

## **Primary outcomes**

### 1

#### **Description**

Clinical signs

#### **Timepoint**

Before the intervention and 14 and 28 days after that

#### **Method of measurement**

Using the Young Mania Rating Scale (YMRS)

### 2

#### **Description**

Sleep quality

#### **Timepoint**

Before the intervention and 14 and 28 days after that

#### **Method of measurement**

Using the Pittsburgh Standard Questionnaire

### 3

#### **Description**

Cognitive function

#### **Timepoint**

Before the intervention and 14 and 28 days after that

#### **Method of measurement**

Using the Montreal Cognitive Assessment (MoCA)

## **Secondary outcomes**

### 1

#### **Description**

Gastric complications

**Timepoint**

28 days after the intervention

**Method of measurement**

By history taking

**Intervention groups****1****Description**

Intervention group: Standard treatment plus tablet levetiracetam 250 mg three times daily for 28 days

**Category**

Treatment - Drugs

**2****Description**

Control group: Standard treatment plus tablet placebo three times daily for 28 days

**Category**

Placebo

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Sina Hospital in Hamadan City

**Full name of responsible person**

Dr Aziz Sharifi

**Street address**

Sina Hospital, Mirzadeh Eshghi Ave.

**City**

Hamadan

**Province**

Hamadan

**Postal code**

6517838695

**Phone**

+98 81 3827 4184

**Email**

azizsharifi91@gmail.com

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Hamedan University of Medical Sciences

**Full name of responsible person**

Dr Saeid Bashirian

**Street address**

Hamadan University of Medical Sciences, Shahid Fahmideh Ave

**City**

Hamadan

**Province**

Hamadan

**Postal code**

6517838695

**Phone**

+98 81 3838 0717

**Email**

info.research@umsha.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Hamedan University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Hamedan University of Medical Sciences

**Full name of responsible person**

Dr Aziz Sharifi

**Position**

Resident of Psychiatry

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Psychiatrics

**Street address**

Sina Hospital, Mirzadeh Eshghi Ave.

**City**

Hamadan

**Province**

Hamadan

**Postal code**

6517838695

**Phone**

+98 81 3827 4184

**Email**

azizsharifi91@gmail.com

**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Hamedan University of Medical Sciences

**Full name of responsible person**

Dr. Mohammad Ahmadpanah

**Position**

Clinical Psychologist

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Psychology

**Street address**

Sina Hospital, Mirzadeh Eshghi Ave.

**City**

Hamadan

**Province**

Hamadan

**Postal code**

6517838695

**Phone**

+98 81 3827 4184

**Email**

m1ahmad2000@gmail.com

**Person responsible for updating data****Contact****Name of organization / entity**

Hamedan University of Medical Sciences

**Full name of responsible person**

Dr Jalal Poorolajal

**Position**

Professor of Epidemiology

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Epidemiology

**Street address**

School of Public Health, Hamadan University of  
Medical Sciences, Shahid Fahmideh Ave

**City**

Hamadan

**Province**

Hamadan

**Postal code**

6517838695

**Phone**

+98 81 3838 0090

**Email**

poorolajal@umsha.ac.ir

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available